69038-76-2

Basic information

• Product Name: 4-broMo-N1-Methylbenzene-1,2-diaMine
• Synonyms: 4-broMo-N1-Methylbenzene-1,2-diaMine
• CAS NO: 69038-76-2
• Molecular Formula: C₇H₉BrN₂
• Molecular Weight: 201.06376
• Mol File: 69038-76-2.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 298.2±30.0 °C(Predicted)
• Appearance: /
• Density: 1.578±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 5.48±0.11(Predicted)
• CAS DataBase Reference: 4-broMo-N1-Methylbenzene-1,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-N1-Methylbenzene-1,2-diaMine(69038-76-2)
• EPA Substance Registry System: 4-broMo-N1-Methylbenzene-1,2-diaMine(69038-76-2)

Safety Data

• Hazardous Substances Data: 69038-76-2(Hazardous Substances Data)

Usage

General Description

4-Bromo-N1-methylbenzene-1,2-diamine is a chemical compound with the molecular formula C7H10BrN2. It is a derivative of benzene and contains a bromine atom, a methyl group, and two amine groups. 4-broMo-N1-Methylbenzene-1,2-diaMine has a variety of industrial applications, including its use as a building block in the synthesis of pharmaceutical drugs and agrochemicals. It is also used in the production of dyes, pigments, and other organic compounds. Additionally, it can be employed as an intermediate in the manufacturing of rubber chemicals and organic solvents. Overall, 4-Bromo-N1-methylbenzene-1,2-diamine has important uses in the chemical and pharmaceutical industries due to its versatile properties and reactivity.

Upstream product

• 53484-26-7 N-methyl-4-bromo-2-nitroaniline 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 875-51-4 4-Bromo-2-nitroaniline 
• 74-89-5 methylamine 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 1026316-27-7 1-benzoyl-3-(5-bromo-2-methylamino-phenyl)-thiourea 
• 53484-15-4 5-bromo-1-methyl-1H-benzo[d]imidazole 
• 944718-31-4 5-bromo-1-methyl-1H-benzo[d][1,2,3]triazole 
• 1396753-41-5 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d][1,2,3]triazole 
• 84712-08-3 5-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-2-one 
• 1107627-02-0 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole 
• 3527-19-3 1,2-dimethyl-1H-benzo[d]imidazole-5-amine 
• 99513-17-4 5-bromo-1,2-dimethyl-1H-benzo[d]imidazole 
• 760212-73-5 5-bromo-1-methyl-2-phenyl-1H-benzo[d]imidazole 

Relevant articles and documents

1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS

The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors

We describe the synthesis of a series of 2-arylbenzimidazole derivatives bearing sulfonamide functionality (4a–d, 7a–c and 10) as well as hydroxamic acid (15a–b), carboxylic acid (16a–b), carboxamide (17a–b) and boronic acid (22a–b and 26) functionalities, which act as human carbonic anhydrase (hCA, EC 4.2.1.1) inhibitors. The newly synthesized benzimidazole derivatives were evaluated against 4 physiologically relevant CA isoforms (hCA I, II, IX, and XII), and especially the sulfonamide-containing benzimidazoles demonstrated intriguing inhibitory activity against tumor associated CA IX and XII with KI values in the range of 5.2–29.3 nM and 9.9–41.7 nM, respectively. Notably, compound 4c was the most potent and selective CA IX (KI = 6.6 nM) and XII (KI = 9.9 nM) inhibitor with a significant selectivity ratio over cytosolic CA I and II isoforms in the range of 3.4–25.2. In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1–121.5 although with KI values in lower micromolar potency (KIs = 0.36–0.85 μM for CA IX/XII).